(RTTNews) - Novocure (NVCR) an oncology company, has received approval from the FDA for its new Head Flexible Electrode transducer arrays, designed for use with its Optune Gio device, which is used in ...

The first treatment of its kind for metastatic NSCLC, Optune Lua is approved for use concurrently with PD-1/PD-L1 inhibitors or docetaxel in adult patients with metastatic NSCLC who progressed on or ...

Optune Lua is FDA approved for use with immunotherapy or docetaxel in metastatic stage IV NSCLC post-platinum treatment. The device uses tumor treating fields to disrupt cancer cell division, offering ...

Lung cancer can be treated with small molecules formulated as pills as well as biological medications that are injected or infused, both as standalone treatments or as part of drug combinations. A ...

CINCINNATI (WKRC) - Patty Young, a brain tumor survivor, expressed her gratitude to the UC Health team for their unwavering support during her treatment. Young, who uses the Optune device, a unique ...

The MarketWatch News Department was not involved in the creation of this content. Optune Pax concomitant with gemcitabine and nab-paclitaxel is the first treatment to be FDA approved in nearly 30 ...

The FDA has granted approval for Novocure‘s wearable medical device, Optune Lua, designed to treat advanced non-small cell lung cancer (NSCLC). The device utilizes portable transducer arrays placed on ...

ROOT, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) approved its new Head Flexible Electrode (HFE) transducer arrays for use ...